MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2026.1806374

Медицинская библиотека · Frontiers in pharmacology · 2026

Amelioration of CKD-induced cardiomyocyte hypertrophy by pegmolesatide: involvement of JAK2/STAT3 inhibition and mitochondrial protection.

Zhang Xinyu, Li Sufang, Lin Tingru, Gan Liangying, Zheng Hanze, Zhu Li, Zuo Li

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Cardiovascular disease represents the leading cause of mortality among patients with chronic kidney disease (CKD). CKD-associated cardiomyopathy is characterized by pathological left ventricular hypertrophy and myocardial fibrosis. Pegmolesatide, a novel pegylated continuous erythropoietin receptor activator, has demonstrated efficacy in treating renal anemia. However, the biological effects of Pegmolesatide beyond erythropoiesis remain poorly characterized.

METHODS

This study established a 5/6 nephrectomy rat model of CKD. The animals were randomized into four groups: sham-operated (Sham), sham-operated plus Pegmolesatide (Sham + Pegmolesatide), CKD model (CKD), and CKD model plus Pegmolesatide (CKD + Pegmolesatide). Cardiac function was assessed by echocardiography, while histopathological examination evaluated cardiac and renal structural changes. Serum renal function parameters were measured using biochemical assays. Myocardial expression of proteins and mRNAs related to fibrosis, hypertrophy, and associated signaling pathways was analyzed by Western blot and quantitative PCR. Furthermore, transcriptomic sequencing of myocardial tissue was performed, and in vitro experiments were conducted using AC16 human cardiomyocytes stimulated with serum from stage 5 CKD patients.

RESULTS

Transcriptomic sequencing suggested that the cardioprotective effects of Pegmolesatide might be associated with improved mitochondrial function and modulation of the STAT3 signaling pathway. Results demonstrated that Pegmolesatide significantly improved cardiac functional parameters and attenuated both myocardial fibrosis and cardiomyocyte hypertrophy. Mechanistic investigations revealed that these cardioprotective effects were mediated through inhibition of JAK2/STAT3 signaling pathway activation and concomitant improvement of mitochondrial function.

DISCUSSION: These findings demonstrate that pegmolesatide exerts anti-anemic effect-independent cardioprotection, offering novel insights into treating CKD-associated cardiomyopathy.

Для цитирования: Zhang Xinyu, Li Sufang, Lin Tingru, Gan Liangying, Zheng Hanze, Zhu Li, Zuo Li. Amelioration of CKD-induced cardiomyocyte hypertrophy by pegmolesatide: involvement of JAK2/STAT3 inhibition and mitochondrial protection.. Frontiers in pharmacology. 2026. DOI: 10.3389/fphar.2026.1806374.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.